Introduction
Verteporfin (Visudyne ® , Novartis AG) is the first light-activated drug shown in large randomized clinical trials to reduce the risk of moderate and severe vision loss compared with no treatment in patients with choroidal neovascularization (CNV). [1] [2] [3] [4] [5] [6] [7] [8] The results of the Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Investigation, composed of two phase III clinical trials in AMD patients, and the Verteporfin In Photodynamic Therapy (VIP) Trial, composed of one trial in AMD patients and one in patients with pathologic myopia, showed that these benefits were sustained through at least 24 months of follow-up, with no additional safety problems identified with even longer follow-up in the TAP Investigation. 5 In addition, among patients presenting with predominantly classic or occult with no classic lesions, verteporfin-treated patients were more likely to have improved visual acuity. For predominantly classic lesion, 6% of treated patients at 12 months and 9% at 24 months experienced moderate vision improvement (at least 3 lines of vision gain) following verteporfin therapy compared with 2% at 12 months and 4% at 24 months of patients who received placebo. 2 For occult with no classic lesions associated with presumed recent disease progression, 5% at 24 months experienced moderate vision improvement following verteporfin therapy compared with 1% who received placebo. 6 For occult with no classic lesions and minimally classic lesions in these trials, this reduced risk of vision loss appeared greater in lesions with smaller size. 9, 10 These vision outcomes were substantiated further by fluorescein angiographic outcomes in which eyes treated with verteporfin showed a greater chance of reduction in lesion growth and absence of leakage from CNV. [1] [2] [3] [4] [5] [6] [7] [8] Verteporfin Roundtable 2003 Participants When these treatment guidelines were published in 2002, 11 it was agreed that the protocols used for patient selection, initial treatment, follow-up, and additional courses of treatment at follow-up had demonstrated verteporfin therapy to be safe and effective in selected patients. However, the guidelines for patient selection and clinical management outside the confines of controlled clinical trials needed to be discussed.
Two roundtable discussion groups, sponsored by Novartis Ophthalmics and QLT Inc.,
were held on July 8-9, 2000 and on March 30- April 1, 2001 to discuss how the scientific data currently available and consensus of expert opinion in the absence of strong scientific data can be applied to clinical practice. The meeting objective was to reach a consensus on guidelines for using verteporfin therapy to treat CNV due to AMD and other causes. The meeting was attended by leaders in ophthalmology from around the world, including retina specialists who were Principal Investigators in the TAP Investigation or the VIP Trial, or both, or who had clinical experience with verteporfin therapy. The results of that meeting were published as guidelines in 2002. Since that time, additional data were published in the peer-review literature that were judged worthy of incorporation into updated guidelines. 9, 10, [12] [13] [14] [15] [16] The current guidelines on patient selection criteria for initial treatment, follow-up monitoring, and decisions regarding when to consider additional courses of treatment at follow-up, as discussed in 2003, are presented in this document to assist ophthalmologists in the identification of patients for whom verteporfin therapy should be considered and to provide suggestions for follow-up of these patients. These guidelines were produced from a draft of consensus points reached at the Roundtables following review by some Principal Investigators of the TAP and VIP Study Groups, with additional 
Patient Selection Criteria
Treatment outcomes are strongly influenced by patient selection. Therefore, identifying those patients most likely to benefit from verteporfin therapy is important. Patient selection is also essential so that those who are unlikely to benefit from treatment are recognized and counseled as such. An algorithm ( Figure 1 ) is presented to summarize the selection criteria in the following section.
The phase III TAP Investigation studied patients with subfoveal CNV due to AMD with evidence of some classic CNV on fluorescein angiography at baseline. In this investigation, verteporfin therapy was shown to reduce the risk of moderate and severe vision loss compared with placebo therapy (Table 1) . However, a greater treatment benefit was observed in patients with predominantly classic subfoveal CNV, particularly, but not exclusively, in the absence of occult CNV. These differences in treatment benefit for predominantly classic compared with minimally classic lesions may be due in part to the larger size of minimally classic lesions compared with predominantly classic lesions at baseline, and in part to the large size of predominantly classic lesions without occult CNV compared with predominantly classic lesions with occult CNV. 3 The AMD arm of the VIP Trial showed that verteporfin therapy reduced the risk of moderate and severe vision loss compared with placebo therapy in patients with occult with no classic CNV and presumed recent disease progression, particularly for cases presenting either with smaller lesions or lower levels of best-corrected visual acuity ( Table 2 ). The pathologic myopia arm of the VIP Trial showed that verteporfin therapy increased the chance of 
a. Predominantly Classic CNV
Verteporfin therapy is recommended to treat eyes that present with a subfoveal lesion that is predominantly classic CNV (area of classic CNV occupying ≥50% of the area of the entire lesion at baseline) ( Table 1) . Subgroup analyses from the TAP Investigation showed a larger treatment benefit for lesions that were predominantly classic CNV with no occult CNV (Table 1) . However, eyes with lesions composed of predominantly classic CNV with an occult CNV component also showed a benefit (Table 1 and Table 3 footnote). Furthermore, predominantly classic lesions without occult CNV were smaller, on average, than those with classic CNV, 3 possibly contributing to the differences in treatment benefit suggested within these subgroups. Therefore, treatment with verteporfin therapy is recommended in predominantly classic CNV with or without evidence of occult CNV, and for both smaller and larger lesions (Figures 2 and 3 ). Verteporfin suggests that treatment might be considered for such patients with rapidly decreasing levels of best-corrected visual acuity.
How should lesion composition influence patient selection in patients with
pathologic myopia?
Lesion composition should not influence patient selection in patients with pathologic myopia as it has not been shown to influence any outcome following verteporfin therapy in these patients. 7, 8 3. How should the size of the lesion influence patient selection?
In the opinion of the Roundtable participants, as well as the TAP and VIP Study Group, 9 treatment of predominantly classic lesions in AMD should not be restricted by the size of the lesion if all other criteria for treatment are met. The TAP Investigation showed that lesion size did not appear to affect the treatment benefit in predominantly classic lesions (Table 4 ). In the clinical trials, the eligibility criterion for lesion size was restricted to lesions with a greatest linear dimension on the retina of up to 5400 µm (the diameter of a 9 MPS disc area circle). The prototype lasers used could not create spot sizes on the retina larger than 6400 µm with most contact lenses. Furthermore, when designing the TAP Investigation, investigators were reluctant to include very large lesions because these tended to have worse baseline visual acuity; hence it may have been difficult to demonstrate benefit if the chance of additional vision loss was small. With the level of knowledge as it stood at the time of trial design, larger lesions were suspected of being at greater risk of harm from the therapy than smaller lesions. The clinical trials data for predominantly classic lesions described above show that these concerns currently have These visual acuity letter scores usually do not accurately reflect Snellen visual acuities obtained in routine practice. 18 "Office" visual acuity does not adequately define the lowest level of visual function for which verteporfin therapy should routinely be considered. In addition, baseline visual acuity did not affect the magnitude of the treatment benefit to a statistically significant degree ( Table 4 ). The results from the controlled clinical trials also showed that verteporfin therapy is beneficial in preserving contrast sensitivity ( The following features at baseline did not affect the magnitude of the treatment benefit in the TAP Investigation or VIP Trial, and therefore were judged not to be relevant in the decision-making process regarding initiation of verteporfin therapy.
a. Patient age
There should be no age cut-off for treatment with verteporfin therapy. Clinical data from the TAP Investigation and VIP Trial indicate that beneficial outcomes after treatment with verteporfin therapy are not influenced by age (Table 4) . However, no data are available for pediatric cases.
b. Systemic arterial hypertension
Hypertension should not be a contraindication for verteporfin therapy as it did not appear to affect beneficial outcomes (Table 4) .
c. Prior laser photocoagulation that does not extend under the center of the foveal avascular zone
Although very few patients with predominantly classic lesions in the TAP Investigation had prior laser photocoagulation with subsequent recurrent subfoveal CNV at baseline, verteporfin therapy appeared to reduce the risk of vision loss for these patients (Table 1 footnote). Therefore, the Roundtable authors would extrapolate these results to recurrent subfoveal CNV lesions and believe these cases should be considered for treatment if they meet all other criteria as specified for new subfoveal CNV. If there is Ophthalmologists who are experienced in managing patients with macular disease and expert at interpreting fundus biomicroscopic findings, color fundus photographs, and fluorescein angiograms should select patients, initiate treatment, and perform follow-up of patients who have received an initial treatment until the situation has stabilized.
When should verteporfin therapy be initiated?
As b. If an additional course of treatment is not judged to be indicated for at least 6 months, then follow-up might be scheduled at 6-month intervals, and eventually 6-to 12-month intervals. If the patient notes visual deterioration between scheduled visits, the ophthalmologist must determine whether or not the patient should return sooner.
The patient must always understand that an additional course of treatment may need to be applied at a future follow-up visit. c. In rare cases, patients may need to return promptly for evaluation if they experience any severe vision decrease soon after treatment. 
When should additional courses of treatment with verteporfin therapy be discontinued?
Additional courses of treatment with verteporfin therapy should not be given when fluorescein leakage is absent from CNV at a follow-up examination. However, the following additional recommendations should be considered for specific situations: -The lesion has a flat, scar-like appearance.
-There is minimal or no subretinal fluid on biomicroscopic examination.
Some experts have suggested that findings from an optical coherence tomography could influence this decision; specifically detection of subretinal fluid through the center of the retina might sway an ophthalmologist more towards wanting to recommend therapy than if no subretinal fluid was detected by an OCT exam. 
For example, a patient is initially treated at month 0 and retreated at month 3. By month 6, minimal leakage (<50% of the area treated at month 3) is seen, the

Is there any situation where conventional laser photocoagulation should be considered after verteporfin therapy?
Following verteporfin therapy, conventional laser photocoagulation might be considered if a relatively small area of well-demarcated fluorescein leakage, either contiguous or non-contiguous to a lesion previously receiving verteporfin therapy, is confined entirely to an extrafoveal location (i.e., no leakage extends within 200 µm of the center of the foveal avascular zone and the area of fluorescein leakage has well-demarcated boundaries for 360° around its entire perimeter).
What photosensitivity precautions should be taken following verteporfin therapy?
Although recommendations made by regulatory authorities may vary between countries, scientific data show that patients should avoid exposure of skin or eyes to direct sunlight or bright indoor light for 48 hours after treatment. Areas of suspected or definite extravasation during infusion of verteporfin should be thoroughly protected from direct light for at least 48 hours after treatment or until any swelling or discoloration has faded, whichever time interval is greater.
What follow-up regimen should be considered for minimally classic lesions or occult with no classic lesions that do not receive treatment?
A retrospective review of the natural history of eyes with subfoveal CNV in which the lesion had a minimally classic composition showed that 40% converted to predominantly classic composition, often within 3 months of initial assessment. In approximately half of the lesions that converted, the lesion size and visual acuity at the time of conversion were at a level where photodynamic therapy with verteporfin was likely to reduce the risk of vision loss compared with continued observation, based on the inclusion criteria and results from the TAP Investigation. 12 These data, while only an approximation of the risk of conversion, would suggest that patients who present with minimally classic lesions, in whom no therapy is recommended initially, should be monitored carefully so that potential conversion to a predominantly classic lesion can be identified promptly. If such a conversion is recognized promptly, verteporfin therapy might be considered at that time since it has been proven to reduce the risk of moderate and severe vision loss in patients with predominantly classic lesions.
In a retrospective review of occult with no classic subfoveal lesions in the VIP Trial, few of these lesions converted to a predominantly classic lesion. with both a larger lesion size and higher (better) level of visual acuity in whom verteporfin therapy usually would not be considered, continued observation, rather than cessation of follow-up, is recommended for two reasons. First, some of the lesions may become predominantly classic with a lesion size and visual acuity for which verteporfin therapy might be considered beneficial. Second, some of the lesions may remain occult with no classic associated with progressive vision loss to a lower level of visual acuity, but still within a visual acuity range and lesion size at which verteporfin therapy would be considered.
What is the impact of other medications in place of or as an adjunct to verteporfin therapy?
Add paragraph here based on AAO Macugen results.
Conclusions
The availability of verteporfin therapy has expanded the range of treatment options for • Mild hepatic impairment usually includes transaminase levels up to 5 times the upper normal limit and bilirubin levels up to 1.5 times the upper normal limit.
• The pharmacokinetic properties of verteporfin have been investigated in subjects who had transaminase levels up to 3 times the upper limit of normal and normal bilirubin levels. There were no significant differences in the pharmacokinetic properties between normal subjects and mildly hepatically-impaired subjects.
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• Verteporfin therapy should be considered carefully in patients with moderate hepatic impairment or biliary obstruction since there has been no experience in these patients.
Verteporfin Poorly demarcated lesion is a lesion in which the demarcation between the boundary of the lesion and retina uninvolved by a lesion component is poorly demarcated (poorly defined). "Poorly defined" is not synonymous with "occult".
Predominantly classic CNV is a lesion in which the area of classic CNV occupies at least 50% of the area of the entire lesion.
Predominantly occult CNV is a lesion in which the area of occult CNV occupies at least 50% of the area of the entire lesion. Predominantly occult CNV is not synonymous with minimally classic CNV. Well-demarcated lesion is a lesion in which the entire boundary of the lesion is well demarcated (or well defined) from retina uninvolved by any lesion component. "Welldefined" is not synonymous with "classic".
